Evolocumab (Repatha)
What clinical trials found
PCSK9 inhibitor (monoclonal antibody)
Injectable, typically every 2-4 weeks. Approved 2015. FOURIER showed evolocumab added to statin therapy further reduced cardiovascular events in people with established ASCVD.
FOURIEREvolocumab (Repatha)
1 community report
Outcome
- Well tolerated & effective100% (n=1)
- Based on 1 report
Would recommend
- Yes100% (n=1)
- Based on 1 report
Coverage outcome
- Approved after appeal100% (n=1)
- Based on 1 report
Price paid per month
$45 – $45, median $45 (n=1)